Literature DB >> 6301501

Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways.

C Reavill, P Jenner, C D Marsden.   

Abstract

Eighteen compounds with dopamine agonist properties were examined in two rat rotational models. In the classical Ungerstedt model, a unilateral 6-hydroxydopamine (60HDA) lesion destroyed nigrostriatal and mesolimbic dopamine pathways on one side. Indirectly acting compounds, amphetamine, amantadine, methylphenidate and S1694, produced ipsiversive rotation, which was inhibited by pretreatment with alpha-methyl-p-tyrosine (AMPT). All other compounds produced contraversive rotation, but the rotation caused by CM 29-712, bromocriptine and ET 495 was reduced by AMPT. In animals with a bilateral 60HDA lesion removing both dopaminergic inputs to nucleus accumbens and the dopaminergic input into one striatum, indirectly acting drugs caused ipsiversive posturing prevented by AMPT, but little rotation. All other compounds produced contraversive rotation, but the effects of CM 29-712, bromocriptine and ET 495 were reduced by AMPT pretreatment. Inhibition of monooxygenase drug metabolising activity utilising SKF-525A inhibited contraversive turning induced by bromocriptine and ET 495 in the unilateral lesion model, but had no effect on rotation caused by apomorphine or CM 29-712. We conclude that, in addition to indirect pre-synaptically acting agonists and direct post-synaptic receptor agonists, there are a small group of compounds which produce rotation associated with direct receptor activation, which is inhibited by disruption of pre-synaptic dopamine function. The mechanism of action of this latter group is not understood, but cannot be attributed solely to active metabolite formation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6301501     DOI: 10.1016/0006-2952(83)90589-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.

Authors:  Andrzej Dekundy; Flora Mela; Martine Hofmann; Wojciech Danysz
Journal:  J Neural Transm (Vienna)       Date:  2014-10-16       Impact factor: 3.575

2.  The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.

Authors:  S A Treseder; M Jackson; P Jenner
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.

Authors:  A F Haase; H E Greiner; C A Seyfried
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-06       Impact factor: 3.000

Review 4.  Parkinson's disease: pathological mechanisms and actions of piribedil.

Authors:  P Jenner
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

Review 5.  Animal models of Parkinson's disease progression.

Authors:  Gloria E Meredith; Patricia K Sonsalla; Marie-Francoise Chesselet
Journal:  Acta Neuropathol       Date:  2008-02-14       Impact factor: 17.088

Review 6.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 7.  Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?

Authors:  Emma Lane; Stephen Dunnett
Journal:  Psychopharmacology (Berl)       Date:  2007-09-25       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.